Niacinamide (vitamin B3): the rare OTC skin active that actually earns its label

What niacinamide actually is

Niacinamide — also called nicotinamide — is one of the two forms of vitamin B3 (the other being niacin, or nicotinic acid). It is water-soluble, cheap, chemically stable, and, unlike niacin, it does not cause the prickly skin flush that high-dose niacin is notorious for. You already carry it: your body converts B3 into a pair of workhorse coenzymes, NAD+ and NADP+ (nicotinamide adenine dinucleotide and its phosphate), which sit at the center of cellular energy production and DNA repair. That last detail is not trivia — it is the thread that runs through almost everything niacinamide does for skin.

For a topical, that profile is close to ideal. It plays nicely with acids, retinoids, and vitamin C; it rarely stings; and it works across a wide pH range. The catch is that “well tolerated and on the label” is not the same as “doing what the label says.” So the useful question is not whether niacinamide is in your serum — it almost certainly is — but which of its advertised jobs the human trials actually back. Within the skin and aging shelf, it is one of the few actives where that question has reassuring answers.

How it signals: four jobs, one molecule

Niacinamide is unusual because it pulls on several different signals at once, and the mechanisms are reasonably well mapped rather than hand-waved. The receptor-and-pathway specifics belong in this section; everywhere else, think of it as a molecule that quietly tells skin to hold water, make less oil, calm down, and stop over-depositing pigment.

First, the barrier. Niacinamide boosts the skin’s synthesis of ceramides and other lipids in the stratum corneum — the outermost layer — and stimulates production of structural proteins like keratin and filaggrin. A better-built outer wall holds water in, which is why the barrier effect shows up as reduced transepidermal water loss (TEWL), the standard instrumental measure of how leaky skin is.² Second, sebum: B3 appears to modulate the activity of sebaceous glands, lowering the rate at which skin pumps out oil.³ Third, inflammation: as a precursor to NAD+, niacinamide supports anti-inflammatory signaling, and one of its metabolites carries anti-inflammatory activity of its own.⁸ Fourth, pigment: rather than blocking the pigment-making enzyme tyrosinase the way many brighteners do, niacinamide interrupts the transfer of finished pigment packets — melanosomes — from melanocytes to surrounding skin cells.⁵

And underneath all of it sits the NAD+ story. By topping up the cell’s NAD+ pool, niacinamide supports DNA repair and helps protect the energy supply that UV light depletes — the mechanism that becomes the spine of the skin-cancer section below.¹ One molecule, several genuinely separate signals: that is exactly why it ended up in everything, and also why “does it work?” has to be answered job by job.

Niacinamide doesn’t resurface or exfoliate. It tops up the cell’s repair currency and reinforces the wall — quiet maintenance, not a chemical peel. That is its strength and the reason it underwhelms people expecting a transformation.

The barrier and oil evidence

The barrier claim is the one I trust most, because it has been measured directly. In a controlled left-right study, patients with atopic dry skin applied a 2% nicotinamide cream to one forearm and plain white petrolatum — a gold-standard occlusive — to the other, twice daily. Nicotinamide significantly lowered transepidermal water loss while petrolatum did not, and it beat petrolatum on stratum-corneum hydration.² That is a meaningful result: it means B3 is not just sitting on top of the skin like a greasy seal, it is improving how well the barrier holds water on its own. For anyone with a compromised barrier — over-exfoliated, retinoid-irritated, eczema-prone — that is the single most useful thing a niacinamide product offers.

Oil control is the second well-supported claim. In a double-blind, placebo-controlled trial, topical 2% niacinamide significantly reduced the sebum excretion rate after two and four weeks in Japanese participants, with a reduction in casual sebum levels seen in a separate Caucasian cohort.³ Worth noting the honesty in the data: the two ethnic groups did not respond identically — sebum excretion rate dropped clearly in one cohort, casual surface oil in the other — which is a reminder that the effect is real but not uniform across skin types. Still, for people whose main complaint is midday shine and clogged pores, the oil-modulating signal is one of the better-grounded reasons to use it.

Acne: surprisingly good for a vitamin

This is the result that should make people take niacinamide seriously rather than treat it as a filler ingredient. In a double-blind multicenter trial, 76 patients with moderate inflammatory acne were randomized to either 4% nicotinamide gel or 1% clindamycin gel — a topical antibiotic — twice daily for eight weeks. The two performed comparably: 82% of the nicotinamide group versus 68% of the clindamycin group were rated improved, with statistically similar reductions in inflammatory lesions (about a 60% drop with nicotinamide versus 43% with clindamycin) and acne severity.⁴

The detail that matters: niacinamide works on inflammatory acne without being an antibiotic. It doesn’t kill bacteria, so it doesn’t drive antibiotic resistance — the exact problem that makes dermatologists wary of leaning on topical clindamycin and erythromycin long-term. So a vitamin gel matching a prescription antibiotic, while sidestepping the resistance liability, is a genuinely strong position. Two honesty caveats keep it from being a slam dunk: this is one trial from 1995 rather than a deep stack of replications, and the win is on inflammatory lesions — the red papules and pustules — not the comedonal clogging that a retinoid handles better. Niacinamide belongs in an acne routine; it does not replace one.

Dark spots: a different lever than the rest

Niacinamide’s approach to hyperpigmentation is mechanistically distinct, and that is what makes it useful as a stacking partner. Most brighteners attack pigment production — hydroquinone, kojic acid, and vitamin C all interfere with tyrosinase, the enzyme that builds melanin. Niacinamide leaves production alone and instead blocks delivery. In a melanocyte-keratinocyte coculture model, niacinamide inhibited the transfer of melanosomes — the packets that carry finished pigment — from pigment cells to skin cells, and a companion split-face human trial found that topical niacinamide produced a dose-dependent, reversible reduction in facial hyperpigmented spots.⁵

“Reversible” is the word to hold onto. Stop using it and the transfer resumes, so the benefit is maintenance, not a permanent erase. The effect is also modest on its own. In a pair of split-face trials, 5% niacinamide reduced hyperpigmentation, but a combination of 5% niacinamide with a second agent (N-undecylenoyl phenylalanine, which works by a different route) significantly outperformed niacinamide alone.⁷ Because it pulls a different lever than the tyrosinase blockers, niacinamide layers cleanly with vitamin C or a retinoid for pigment — it is a teammate, not a soloist. If you want the deep comparison of how these actives stack against each other, the supplements reference and the Manual map the combinations.

Redness and rosacea: the weakest claim

Here the marketing gets ahead of the evidence. “Reduces redness” is on nearly every niacinamide bottle, usually justified by improvements in “red blotchiness” seen in general photoaging trials.⁶ For diffuse facial redness in otherwise healthy skin, that is a plausible secondary benefit of a better barrier — calmer skin is less reactive. But for clinical rosacea, the direct evidence is thin. The most-cited supportive study used not plain niacinamide but a metabolite, 1-methylnicotinamide, as a 0.25% gel in an open-label pilot of 34 patients, reporting improvement in 26 — encouraging, but uncontrolled, small, and a different molecule.⁸ Niacinamide turns up in rosacea management reviews mainly as a supportive barrier agent, not a primary therapy.⁸

So state it plainly: niacinamide may help mild, barrier-driven redness as a byproduct of strengthening the skin, but it is not a proven rosacea treatment. If you have true rosacea — persistent central-face redness, visible vessels, flushing, papulopustular flares — that is a dermatology conversation, and the evidence-based topicals for it are different drugs.

Oral B3 and skin-cancer prevention: the ONTRAC trial

This is the most important — and most misunderstood — use of vitamin B3, and it has nothing to do with serums. The ONTRAC trial, published in the New England Journal of Medicine, was a proper phase 3, double-blind, randomized, placebo-controlled study. It enrolled 386 high-risk participants — people who had already had at least two non-melanoma skin cancers in the previous five years — and gave them either 500 mg of oral nicotinamide twice daily or placebo for 12 months. At 12 months, the rate of new non-melanoma skin cancers (basal-cell plus squamous-cell carcinomas) was 23% lower in the nicotinamide group than in the placebo group, and the number of precancerous actinic keratoses fell as well, with no notable difference in side effects.¹

The mechanism is the NAD+ story made concrete: oral nicotinamide replenishes the cellular energy that ultraviolet light depletes, supports DNA repair after UV damage, and protects against UV-induced suppression of skin immunity.¹ It is biologically coherent and the trial was well designed, which is why this finding has held up where so many supplement claims collapse.

Now the caveats that keep it honest. The benefit appeared only during treatment and disappeared once the nicotinamide was stopped, so it is ongoing maintenance, not a one-time fix. The population was specifically high-risk — this is not evidence that healthy, low-risk people should take gram-level B3 to prevent a cancer they were unlikely to get. And it was a single large trial; a subsequent phase 3 prevention trial in organ-transplant recipients (a different, immunosuppressed high-risk group) found no benefit — identical rates of new keratinocyte cancers on nicotinamide and placebo — which is exactly why I grade this finding as moderate rather than locked-in.⁹ The takeaway is precise: in people with a heavy history of non-melanoma skin cancers, oral nicotinamide is a cheap, well-tolerated, clinician-supervised option worth discussing — not a general-population supplement, and not a substitute for sun protection.

Where it fits: a tiered view

It helps to place niacinamide honestly on a spectrum of how settled the evidence is and who it is for.

Foundational — the no-brainer barrier and oil use. A topical 2–5% niacinamide is one of the lowest-risk, best-supported additions to a routine for anyone with a compromised barrier, oily or acne-prone skin, or sensitivity to stronger actives. The TEWL and sebum data are real, it rarely irritates, and it buffers the sting of the retinoids and acids that do the heavier lifting.²³ This is the tier where niacinamide genuinely earns its place on the label.

Targeted — acne and pigment support. If your concern is inflammatory acne or stubborn dark spots, niacinamide is a credible non-antibiotic contributor — comparable to topical clindamycin for inflammatory lesions, and a clean stacking partner for pigment because it works by a different mechanism than the tyrosinase blockers.⁴⁵ Expect a supporting-cast contribution measured over weeks, not a standalone cure.

Clinical — oral nicotinamide for skin-cancer prevention. This is a medical use, not a cosmetic one. For people with a documented heavy history of non-melanoma skin cancers, oral nicotinamide at the ONTRAC dose has real randomized support — but it is a conversation to have with a dermatologist, weighed against your actual risk, and continued only as long as the supervising clinician advises.¹

Grey areas and open questions

Concentration is mostly marketing above 5%. The barrier, sebum, and pigment trials used 2–5% topical niacinamide.²³⁶ Serums advertising 10% or 20% are not riding a stronger evidence base — they are riding a number on the bottle, and high concentrations are more likely to irritate than to help. There is no good trial showing 10% beats 5% for any of these endpoints.

The acne and rosacea data are thin where it counts. The flagship acne comparison is a single multicenter trial from 1995, not a stack of modern replications.⁴ The rosacea support leans on a small open-label pilot of a B3 metabolite rather than controlled trials of niacinamide itself.⁸ Both uses are plausible; neither is settled.

Oral prevention didn’t replicate everywhere. ONTRAC was positive in immunocompetent high-risk patients,¹ but a later phase 3 trial in organ-transplant recipients did not show the same benefit,⁹ and there is no evidence supporting gram-level oral B3 for skin-cancer prevention in low-risk, healthy people. The result is real but bounded, and population matters enormously.

Population gaps. Much of the topical work is in small, often industry-affiliated cosmetic-science studies; there is limited long-term safety-and-efficacy data for years of continuous use, and the trials skew toward narrow demographics. As with most cosmetic actives, the effect sizes are modest and the samples are small.

What this article is not saying

This is not “niacinamide doesn’t work.” It is, in fact, one of the few over-the-counter skin actives with direct, measured human data behind its core claims — barrier repair, oil control, inflammatory acne, and pigment transfer all have real trial support, and the oral skin-cancer finding is one of the stronger results in all of dermatology supplementation. Dismissing it is as wrong as overselling it.

This is not “niacinamide will transform your skin.” It is a quiet maintenance ingredient, not a resurfacing one. It will not erase wrinkles the way a retinoid can, it will not replace your sunscreen, and it will not reliably cure rosacea. A modest, well-tolerated, evidence-backed edge is exactly what it offers — and exactly what the 10%-serum marketing inflates.

And this is not a dosing prescription. The oral skin-cancer use in particular is a clinician-supervised decision for high-risk patients, not a self-experiment with megadose B3. If you have persistent acne, rosacea, or any new or changing skin lesion, that deserves a dermatologist — the point of this piece is to tell you what the trials show and where they stop, so your expectations, and your shelf, can be honest ones.